메뉴 건너뛰기




Volumn 60, Issue 5, 2006, Pages 308-310

Late response to Omalizumabin a patient with severe persistent allergic asthma;Risposta tardiva alla terapia con Omalizumab in paziente con asma allergico grave persistente

Author keywords

Add on treatment; Late responderslife; Omalizumab

Indexed keywords

BUDESONIDE; IMMUNOGLOBULIN E; OMALIZUMAB; PREDNISONE; SALBUTAMOL; STEROID;

EID: 34047244019     PISSN: 11270810     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article
Times cited : (2)

References (6)
  • 1
  • 2
    • 0042160026 scopus 로고    scopus 로고
    • Asthma deaths; persistent and preventable mortality
    • Sidebotham HJ, Roche WR. Asthma deaths; persistent and preventable mortality. Histopathology 2003; 43:105-17.
    • (2003) Histopathology , vol.43 , pp. 105-117
    • Sidebotham, H.J.1    Roche, W.R.2
  • 3
    • 85030598488 scopus 로고    scopus 로고
    • Global strategy for asthma management and prevention
    • Global Initiative for Asthma GINA
    • Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. NIH Pubblication 02-3659, Updated 2005.
    • (2005) NIH Pubblication 02-3659, Updated
  • 4
    • 33745019865 scopus 로고    scopus 로고
    • Walzer S, Monteil M, Phelan K , Lasserson TJ, Walters EH. Anti-IgE for chronic asthma in adults and children. Cochrane Database Syst Rev 2006, Apr 19(2):CD003559.
    • Walzer S, Monteil M, Phelan K , Lasserson TJ, Walters EH. Anti-IgE for chronic asthma in adults and children. Cochrane Database Syst Rev 2006, Apr 19(2):CD003559.
  • 5
    • 20044362008 scopus 로고    scopus 로고
    • Humbert M, Beasley R, Ayres J, Slavin R,_Bert JH, Bousquet J, Beeh K-M, Ramos S, Canonica GW, Hedgecock S, Fox H, Blogg M, Surrey K. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): Innovate. Allergy 2005 ; 60:309-16.
    • Humbert M, Beasley R, Ayres J, Slavin R,_Bert JH, Bousquet J, Beeh K-M, Ramos S, Canonica GW, Hedgecock S, Fox H, Blogg M, Surrey K. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): "Innovate". Allergy 2005 ; 60:309-16.
  • 6
    • 0026543164 scopus 로고
    • Evaluation of impairment of health-related quality of life in asthma: Development of a questionnaire for use in clinical trials
    • Juniper EF, Guyatt GH, Epstein RS, Ferrie PJ, Jaeschke R, Hiller TK. Evaluation of impairment of health-related quality of life in asthma: development of a questionnaire for use in clinical trials. Thorax 1992;47:76-83.
    • (1992) Thorax , vol.47 , pp. 76-83
    • Juniper, E.F.1    Guyatt, G.H.2    Epstein, R.S.3    Ferrie, P.J.4    Jaeschke, R.5    Hiller, T.K.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.